skip to Main Content
Dr. Sapna Syngal in a portait photo in her office

GENERATE Trial Expands Eligibility

Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.

Newsfeed image, light gray text on dark gray background

PARP Inhibitors in Pancreatic Cancer

Tanios Bekaii-Saab, M.D., of the Mayo Clinic in Phoenix, AZ, explains the importance of research into treatment with PARP inhibitors in a short and informative video. Watch the video . . .

Newsfeed image, light gray text on dark gray background

IARC Identifies Eight Additional Cancer Sites Linked to Overweight and Obesity

Based on a systematic review of the published scientific literature, the Working Group for IARC Handbooks of Cancer Prevention Volume 16: Body Fatness provided the latest evaluation of the cancer-preventive effects of the absence of excess body fatness. A summary of the results is published today in The New England Journal of Medicine. A Working…

Newsfeed image, light gray text on dark gray background

Pancreatic Cancer Trial to Make Tumors More Sensitive to Treatment

The trial, which launches in the UK today, will treat pancreatic cancer patients whose cancer has grown too big to be removed by surgery but has not yet spread to other parts of the body. The team will give patients on the trial a drug called olaparib, in addition to the standard treatment of chemotherapy…

Back To Top